Nelson+ is officially live in the UK
Congratulations on a team effort! After various group meetings and integration tests, we are officially live in the UK with the University College London Hospitals NHS Foundation Trust (UCLH) located in the London Borough of Camden. UCLH is a teaching and research hospital closely associated with next-door located University College London (UCL). We believe in a strong partnership in the UK, as UCLH is one of the UK’s leading hospitals and shows with her SUMMIT Study her determination to continuously innovate the early detection of lung cancer.
With UCLH’s participation in the NHS England Targeted Lung Health Check programme (TLHC), UCLH will be able to further foster her leading position in the Lung Cancer Screening (LCS) landscape. The TLHC is an innovative and highly important pilot programme inviting identified high-risk individuals for a lung health check, and optional subsequent CT scan, to contribute to the improvement of early diagnosis and survival of lung cancer, set out in the NHS Long Term Plan. The programme was set up after the successful UK Lung Cancer Screening trial (UKLS) that provided a springboard for implementing LCS programmes in the UK.
Both the TLHC and the SUMMIT Study need to be supported by not only an excellent end-to-end data management and workflow screening solution, but also by a partner that is willing to demonstrate the same level of commitment and determination as UCLH to innovate the screening programme, and thereby improve the early detection of lung cancer. We have provided UCLH with our end-to-end data management and workflow solution, the Nelson+ platform. On one hand, the Nelson+ platform has been developed as a general and therefore scalable screening platform based on 30+ years of experience in cancer screening. On the other hand, the Nelson+ software has been specifically customized to high-quality lung cancer screening with the use in the EU H2020 4-IN-THE-LUNG-RUN project and 20+ year track record with the NELSON study and cardiovascular screening trials.
We are looking forward to a fruitful collaboration with UCLH!
